An overwhelming number of medical stakeholders have given their two cents to US regulators about how artificial intelligence and machine learning products should be regulated. A common theme across the board is they want more clarity and agreement on key terms, as well as a soft regulatory touch when it comes to AI/ML software updates when compared to requirements for traditional medical devices.
In April, the US Food and Drug Administration published a discussion paper on how it's thinking about regulating AI/ML products....
